Men often have trouble urinating as they get older. Coupled with persistent low back pain, or even repeated attacks after medical treatment, they should be on the lookout for any sign of prostate cancer.
Gao Jianzhang, chief physician of the Department of Urology of the Department of Surgery of the Third Military General Hospital, pointed out that a 50-year-old man who visited the orthopedic department for low back pain was recently suspected of having bone metastases from a tumor. 600, which is 150 times higher than the normal standard, and the patient’s bones were found to have multiple metastases, which was identified as a high-risk metastatic prostate cancer. Most Chinese consider prostate cancer to be a milder form of cancer. In fact, not only does prostate cancer rank fifth among the top ten cancers for men in Taiwan, but many patients delay medical treatment due to neglect of symptoms, resulting in a late stage when detected. Gao Jianzhang explained that nearly 30% of patients in China have metastatic prostate cancer, and most of them have no obvious symptoms before diagnosis, or they consider dysuria and difficulty urinating as prostate hypertrophy. Doctors recall that a portion of the population with metastatic prostate cancer is at high risk, with a higher rate of hormonal therapy failure, a faster PSA rise, and more dangerous disease progression. Compared to non-high-risk metastatic prostate cancer, the difference in survival time between high-risk metastatic prostate cancer and non-high-risk metastatic prostate cancer is nearly 3 years. “Prostate cancer” has three characteristics: the first is a Gleason score greater than 8, the second is multiple bone metastasis, and the third is visceral metastasis. The Gleason score is a prognostic indicator used to evaluate prostate cancer, which is related to the differentiation of tumor cells. Prostate cancer with a score of 8 or more represents a recurrence rate and worse disease progression. In terms of tumor metastasis, next to lymph, bone is the most common site of prostate cancer metastasis. The proportion of prostate cancer with visceral metastases is smaller, and once metastases to the lungs, liver and brain occur, this indicates a higher degree of malignancy. As long as the Gleason score is more than 8 points, multiple bone metastases and 2 visceral metastases are reached, it belongs to high-risk metastatic prostate cancer. Because of the rapid progression of high-risk prostate cancer, treatment must be proactively initiated beforehand. Gao Jianzhang explained that metastatic prostate cancer is generally treated with hormones and the average survival time is about 4 years. However, when broken down into high-risk and low-risk categories, the life expectancy of high-risk metastatic prostate cancer is no more than 3 years, while the survival of low-risk groups can be 5 or 6 years. . It is therefore expected that for high-risk metastatic prostate cancer, in addition to the use of existing hormone therapy, a new generation of hormone inhibitors will also be used at the same time. Gao Jianzhang said that patients who use a new generation of hormone inhibitors in combination have an average survival time of nearly a year and a half longer than those who do not use the combination treatment.Gao Jianzhang explained that prostate cancer is a hormone-based tumor and patients with metastatic prostate cancer have systemic therapy needed to reduce the hormone production required by the tumor. Traditional hormonal therapy involves injecting drugs to suppress male hormones. The new generation of hormone inhibitors can inhibit not only the hormone secretion of the testicles, but also about 5% of the male hormones produced by adrenaline. In order to achieve the goal of further reducing male hormones in the blood and obtaining better therapeutic effects, Gao Jianzhang pointed out that as long as the patient meets the indicators of high-risk metastatic prostate cancer, that is, Gleason score higher than 8 points, multiple bone metastases and visceral metastases, two of them will be recommended for traditional hormone therapy and new generation hormone suppression. The overall mean survival rate will increase even more with combined treatment. Gao Jianzhang explained that the health insurance has passed the high-risk metastatic prostate cancer this year, and can apply for a new generation of hormone inhibitors to pay, but the bone metastases must be more than 4, and one of them is outside the axial bone. Discuss your condition and choose a treatment strategy that suits you Gao Jianzhang urged that men should not take it lightly as long as they have conscious urination problems or unexplained low back pain. They think it’s because their bodies are aging and ignore the underlying diseases. Take a more ideal treatment.